WO2013036282A3 - Downregulation of inflammatory micrornas by ilt3 - Google Patents

Downregulation of inflammatory micrornas by ilt3 Download PDF

Info

Publication number
WO2013036282A3
WO2013036282A3 PCT/US2012/024771 US2012024771W WO2013036282A3 WO 2013036282 A3 WO2013036282 A3 WO 2013036282A3 US 2012024771 W US2012024771 W US 2012024771W WO 2013036282 A3 WO2013036282 A3 WO 2013036282A3
Authority
WO
WIPO (PCT)
Prior art keywords
mirs
discovered
ilt3
downregulation
providing
Prior art date
Application number
PCT/US2012/024771
Other languages
French (fr)
Other versions
WO2013036282A2 (en
Inventor
Nicole Suciu-Foca
Chih-Chao Chang
George Vlad
Eric Koonming HO
Original Assignee
The Trustees Of Columbia University In The City Of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of Columbia University In The City Of New York filed Critical The Trustees Of Columbia University In The City Of New York
Publication of WO2013036282A2 publication Critical patent/WO2013036282A2/en
Publication of WO2013036282A3 publication Critical patent/WO2013036282A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

It has been discovered that inhibition of two or more specific inflammatory miRs (30b, 21, 146a, and 155) suppresses T cell proliferation, promotes T cell anergy or induces the formation of suppressor T cells, thereby providing a focused therapy with minimal toxicity for disorders associated with abnormally high immune responses. The corollary involves increasing the level of certain proinflammatory miRs thereby providing methods for immuno stimulation. It has also been discovered that significant increases of serum miR21 which occur in heart allograft rejection can be used to identify patients that have this disorder without requiring a biopsy.
PCT/US2012/024771 2011-09-07 2012-02-10 Downregulation of inflammatory micrornas by ilt3 WO2013036282A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161532031P 2011-09-07 2011-09-07
US61/532,031 2011-09-07

Publications (2)

Publication Number Publication Date
WO2013036282A2 WO2013036282A2 (en) 2013-03-14
WO2013036282A3 true WO2013036282A3 (en) 2014-04-24

Family

ID=47832746

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/024771 WO2013036282A2 (en) 2011-09-07 2012-02-10 Downregulation of inflammatory micrornas by ilt3

Country Status (1)

Country Link
WO (1) WO2013036282A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1799840A4 (en) 2004-09-03 2009-02-18 Univ Columbia Ilt3 polypeptides and uses thereof
WO2013033734A1 (en) 2011-09-02 2013-03-07 The Trustees Of Columbia University In The City Of New York Diagnosis and Treatment of Cancer Expressing ILT3 or ILT3 Ligand
CN103571955A (en) * 2013-10-28 2014-02-12 深圳市第二人民医院 Application of DUSP-9 (dual-specificity phosphatase-9) gene to detection of renal clear cell carcinoma
WO2015074083A1 (en) * 2013-11-18 2015-05-21 The Trustees Of Columbia University In The City Of New York Methods for diagnosing t cell-mediated inflammation
EP3119904A1 (en) * 2014-03-17 2017-01-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting acute rejection in heart recipients
BR112016023634A2 (en) * 2014-04-10 2017-10-17 Univ Pennsylvania use of micro-ribonucleic acid (mirna) to diagnose transplant rejection and tolerance of immunosuppression therapy
CN105087477A (en) * 2015-05-21 2015-11-25 王松灵 Application of mesenchymal stem cell modified by miR-21 antisense nucleotide
US10765742B2 (en) 2015-07-17 2020-09-08 The Trustees Of Columbia University In The City Of New York Methods of treating CD166-expressing cancer
PE20211604A1 (en) 2018-07-09 2021-08-23 Five Prime Therapeutics Inc ILT4 UNION ANTIBODIES

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009100955A1 (en) * 2008-02-14 2009-08-20 Istituto Superiore di Sanità Antisense rna targeting cxcr4
US20100086928A1 (en) * 2006-12-20 2010-04-08 The Brigham And Women's Hospital, Inc. Detection of organ rejection
US20100202973A1 (en) * 2007-05-18 2010-08-12 Karolinska Institutet Innovations Ab Microrna molecules associated with inflammatory skin disorders
WO2010130351A1 (en) * 2009-05-15 2010-11-18 Bayer Schering Pharma Ag Micrornas as biomarkers and therapeutic targets for heart failure

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100086928A1 (en) * 2006-12-20 2010-04-08 The Brigham And Women's Hospital, Inc. Detection of organ rejection
US20100202973A1 (en) * 2007-05-18 2010-08-12 Karolinska Institutet Innovations Ab Microrna molecules associated with inflammatory skin disorders
WO2009100955A1 (en) * 2008-02-14 2009-08-20 Istituto Superiore di Sanità Antisense rna targeting cxcr4
WO2010130351A1 (en) * 2009-05-15 2010-11-18 Bayer Schering Pharma Ag Micrornas as biomarkers and therapeutic targets for heart failure

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PHAM ET AL.: "Essentials of Genomic and Personalized Medicine.", CLINICAL CARDIOLOGY (PHAM), 2010, pages 328 - 334, Retrieved from the Internet <URL:http://books.google.com/books?id=EIBwJ2ISRrACBpg=PA33281pg=PA3328dq=%222R/3A%22+rejection&source=bl&ots=fxhiOVcMXB&sig=W6gkktaDByqzOAbur7GyjqDias8&hl=en&sa=X&ei=J2GhT4-tM6PW2gWKq_DFCO&sqi=28ved=OCCgQ6AEwAQ#v=snippet&q=%222R%2F3A%22%208f=false> [retrieved on 20120502] *

Also Published As

Publication number Publication date
WO2013036282A2 (en) 2013-03-14

Similar Documents

Publication Publication Date Title
WO2013036282A3 (en) Downregulation of inflammatory micrornas by ilt3
PH12018500401B1 (en) Antibodies specific for tgf-beta
MX2019014009A (en) Improved methods for manufacturing adoptive cell therapies.
WO2013006474A3 (en) Requlatora t cells and methods of identifying and isolating them using cd6 -expression or the combination of cd4, cd25 and cd127
EP4279579A3 (en) Methods and compositions for natural killer cells
PH12016500783A1 (en) Suspension and clustering of human pluripotent stem cells for differentation into pancreatic endocrine cells
WO2013124817A3 (en) MicroRNAS FOR THE GENERATION OF ASTROCYTES
WO2014028453A3 (en) Natural killer cells and uses thereof
WO2012149546A3 (en) Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
EP2552483A4 (en) Antibody-based depletion of antigen-presenting cells and dendritic cells
MX355606B (en) Methods for diagnosing and treating eye-length related disorders.
EP3799871A3 (en) Pyrazol-3-ones that activate pro-apototic bax
EP2555627A4 (en) Methods of treating cancer
PH12015501282B1 (en) Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
WO2008052740A3 (en) Method for stimulating dendritic cells and cell product thus obtained for the autologous immunotherapy of solid human tumours
MX2016005824A (en) Cell culture method.
WO2013109055A3 (en) Canine-derived natural killer cells, and mass proliferation method thereof
MX2013011421A (en) Pyrazolo pyrimidine derivatives.
MX2015001488A (en) Treating inflammation using serelaxin.
WO2015120436A3 (en) Stat3 phosphorylation during graft-versus-host disease
MX347439B (en) An antibody inducing antigen-specific t cell tolerance and use thereof.
GR1008177B (en) Method for the treatment of fir-based extract exhibiting biological action - use of same for the cure of human and animal diseases
WO2013093512A3 (en) Vaccine - screening method
MX351765B (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease.
WO2012136351A8 (en) Tapentadol for treating pain associated with trigeminal neuralgia

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12830237

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12830237

Country of ref document: EP

Kind code of ref document: A2